Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 118
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
1.
Behav Processes ; 218: 105044, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38679343

RESUMO

The goal is to understand consequences of anabolic-androgenic steroid (AAS) abuse on cognitive function, using rats as a model. Economic decision making was evaluated in an operant test of effort value discounting, where subjects choose between 2 levers that deliver large and small rewards differing in maximum value and reward contrast. The hypothesis is that chronic high-dose testosterone increases preference for large rewards. Male rats were treated chronically with testosterone (7.5 mg/kg) or vehicle. Initially, all rats preferred the large reward lever when large and small rewards remained fixed at 3 and 1 sugar pellets, respectively. When different reward values were introduced, and with increasing response requirements, testosterone-treated rats made fewer responses for the large reward, and increased omissions. They earned fewer rewards overall. To determine if testosterone impairs memory, rats were tested for recognition memory with the novel object recognition and social transmission of food preference tasks, and for spatial memory with the radial arm maze and Morris water maze. There was not effect of chronic high-dose testosterone on any memory task. These results suggest that testosterone shifts economic decision making towards larger rewards even when they are disadvantageous, but does not alter memory in rats.


Assuntos
Tomada de Decisões , Recompensa , Testosterona , Animais , Masculino , Testosterona/farmacologia , Ratos , Tomada de Decisões/efeitos dos fármacos , Tomada de Decisões/fisiologia , Memória/efeitos dos fármacos , Condicionamento Operante/efeitos dos fármacos , Ratos Long-Evans
2.
Neurobiol Learn Mem ; 180: 107408, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33609742

RESUMO

The present experiments investigated the effects of repeated amphetamine exposure on neural networks mediating different forms of learning and memory. Different components of these networks were assessed using various functional assays. The hypothesis was that abnormal dendritic changes in nucleus accumbens, medial prefrontal cortex, and hippocampus mediated by repeated amphetamine exposure would produce impairments on forms of learning and memory dependent on neural circuits relying on these brain systems, and have little or no effect on other forms of learning not dependent on these networks. Surprisingly, the results showed that many of the dendritic changes normally found in the nucleus accumbens, prefrontal cortex, and hippocampus following repeated amphetamine exposure were reversed back to control levels following extensive multi-domain cognitive training. Learning and memory functions associated with different neural networks also appeared normal except in one case. A neural network that includes, but is not limited to, the basolateral amygdala and nucleus accumbens was dysfunctional in rats repeatedly exposed to amphetamine despite the reversal of the majority of dendritic changes in the nucleus accumbens following cognitive training. Importantly, an increase in spine density that normally occurs in these brain regions following repeated amphetamine exposure remained following extensive cognitive training, particularly in the nucleus accumbens.


Assuntos
Anfetamina/farmacologia , Estimulantes do Sistema Nervoso Central/farmacologia , Dendritos/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Memória/efeitos dos fármacos , Núcleo Accumbens/efeitos dos fármacos , Córtex Pré-Frontal/efeitos dos fármacos , Animais , Complexo Nuclear Basolateral da Amígdala/efeitos dos fármacos , Comportamento Animal/efeitos dos fármacos , Condicionamento Clássico/efeitos dos fármacos , Espinhas Dendríticas/efeitos dos fármacos , Medo , Hipocampo/patologia , Aprendizagem/efeitos dos fármacos , Aprendizagem em Labirinto/efeitos dos fármacos , Vias Neurais/efeitos dos fármacos , Vias Neurais/patologia , Plasticidade Neuronal/efeitos dos fármacos , Núcleo Accumbens/patologia , Córtex Pré-Frontal/patologia , Ratos
4.
J Vis Exp ; (160)2020 06 04.
Artigo em Inglês | MEDLINE | ID: mdl-32568250

RESUMO

Cognitive impairment is one of the most common comorbidities in temporal lobe epilepsy. To recapitulate epilepsy-associated cognitive decline in an animal model of epilepsy, we generated pilocarpine-treated chronic epileptic mice. We present a protocol for three different behavioral tests using these epileptic mice: novel object location (NL), novel object recognition (NO), and pattern separation (PS) tests to evaluate learning and memory for places, objects, and contexts, respectively. We explain how to set the behavioral apparatus and provide experimental procedures for the NL, NO, and PS tests following an open field test that measures the animals' basal locomotor activities. We also describe the technical advantages of the NL, NO, and PS tests with respect to other behavioral tests for assessing memory function in epileptic mice. Finally, we discuss possible causes and solutions for epileptic mice failing to make 30 s of good contact with the objects during the familiarization sessions, which is a critical step for successful memory tests. Thus, this protocol provides detailed information about how to assess epilepsy-associated memory impairments using mice. The NL, NO, and PS tests are simple, efficient assays that are appropriate for the evaluation of different kinds of memory in epileptic mice.


Assuntos
Epilepsia/induzido quimicamente , Memória/efeitos dos fármacos , Agonistas Muscarínicos/efeitos adversos , Pilocarpina/efeitos adversos , Animais , Modelos Animais de Doenças , Masculino , Camundongos
5.
Iran Biomed J ; 24(4): 220-8, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32306720

RESUMO

Background: The most important cause of neurodegeneration in Alzheimer's disease (AD) is associated with inflammation and oxidative stress. Probiotics are microorganisms that are believed to be beneficial to human and animals. Probiotics reduce oxidative stress and inflammation in some cases. Therefore, this study determined the effects of probiotics mixture on the biomarkers of oxidative stress and inflammation in an AD model of rats. Methods: In this study, 50 rats were allocated to five groups, namely control, sham, and AD groups with Aß1-40 intra-hippocampal injection, as well as AD + rivastigmine and AD + probiotics groups with Aß1-40 intra-hippocampal injection and 2 ml (1010 CFU) of probiotics (Lactobacillus reuteri, Lactobacillus rhamnosus, and Bifidobacterium infantis) orally once a day for 10 weeks. MWM was used to assess memory and learning. To detect Aß plaque, Congo red staining was used. Oxidative stress was monitored by measuring the MDA level and SOD activity, and to assess inflammation markers (IL-1ß and TNF-α) in the hippocampus, ELISA method was employed.. Results: Spatial memory improved significantly in treatment group as measured by MWM. Probiotics administration reduced Aß plaques in AD rats. MDA decreased and SOD increased in the treatment group. Besides, probiotics reduced IL-1ß and TNF-α as inflammation markers in the AD model of rats. Conclusion: Our data revealed that probiotics are helpful in attenuating inflammation and oxidative stress in AD.


Assuntos
Doença de Alzheimer/fisiopatologia , Doença de Alzheimer/terapia , Biomarcadores/metabolismo , Inflamação/patologia , Memória , Estresse Oxidativo , Probióticos/uso terapêutico , Peptídeos beta-Amiloides/metabolismo , Animais , Modelos Animais de Doenças , Hipocampo/patologia , Interleucina-1beta/metabolismo , Masculino , Malondialdeído/metabolismo , Memória/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Probióticos/farmacologia , Ratos Wistar , Aprendizagem Espacial/efeitos dos fármacos , Superóxido Dismutase/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
6.
Arq Neuropsiquiatr ; 77(1): 19-24, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30758438

RESUMO

AIM: Our aim was to determine whether there is a relationship between vitamin D [25(OH)D] and cognitive functioning in women with low 25(OH)D levels. METHODS: Ninety female patients, 25-45 years of age, who attended our outpatient clinic and had 25(OH)D levels < 30 ng/mL, were included. The Montreal Cognitive Assessment (MoCA) scale was used to determine cognitive functioning; the scale is divided into seven subgroups. Patients were divided into three subgroups according to their 25(OH)D levels. After a three-month period of 25(OH) D replacement, the patients underwent a re-evaluation using the MoCA scale. RESULTS: The total MoCA score before treatment was significantly different from the score after treatment (p < 0.05). Language and delayed recall functions were significantly different before and after treatment (p < 0.05). CONCLUSION: Vitamin D levels were related to cognitive functioning in our study group.


Assuntos
Cognição/efeitos dos fármacos , Deficiência de Vitamina D/psicologia , Vitamina D/farmacologia , Adulto , Escolaridade , Feminino , Humanos , Memória/efeitos dos fármacos , Testes de Estado Mental e Demência , Pessoa de Meia-Idade , Estudos Prospectivos , Estatísticas não Paramétricas , Resultado do Tratamento , Vitamina D/sangue
7.
Arq. neuropsiquiatr ; 77(1): 19-24, Jan. 2019. tab
Artigo em Inglês | LILACS | ID: biblio-983879

RESUMO

ABSTRACT Aim: Our aim was to determine whether there is a relationship between vitamin D [25(OH)D] and cognitive functioning in women with low 25(OH)D levels. Methods: Ninety female patients, 25-45 years of age, who attended our outpatient clinic and had 25(OH)D levels < 30 ng/mL, were included. The Montreal Cognitive Assessment (MoCA) scale was used to determine cognitive functioning; the scale is divided into seven subgroups. Patients were divided into three subgroups according to their 25(OH)D levels. After a three-month period of 25(OH) D replacement, the patients underwent a re-evaluation using the MoCA scale. Results: The total MoCA score before treatment was significantly different from the score after treatment (p < 0.05). Language and delayed recall functions were significantly different before and after treatment (p < 0.05). Conclusion: Vitamin D levels were related to cognitive functioning in our study group.


RESUMO Objetivo: Nosso objetivo foi determinar se existe uma relação entre a vitamina D [25(OH)D] e o funcionamento cognitivo em mulheres com baixos níveis de 25(OH)D. Métodos: Noventa pacientes do sexo feminino (25-45 anos de idade) que se apresentaram ao nosso ambulatório e tinham níveis de 25(OH)D <30 ng/mL foram incluídas. A escala de avaliação cognitiva de Montreal (MoCA) foi usada para determinar o funcionamento cognitivo; a escala é dividida em sete subgrupos. As pacientes foram divididas em três subgrupos de acordo com seus níveis de 25(OH)D. Após um período de três meses de reposição de 25(OH)D, as pacientes foram submetidas a uma reavaliação de acordo com a escala MoCA. Resultados: O escore total da MoCA antes do tratamento foi significativamente diferente do escore após o tratamento (p <0,05). As funções de idioma e recordação atrasada foram mais significativamente diferentes entre antes e depois do tratamento (p <0,05). Conclusão: O nível de vitamina D foi relacionado ao funcionamento cognitivo em nosso grupo de estudo.


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Vitamina D/farmacologia , Deficiência de Vitamina D/psicologia , Cognição/efeitos dos fármacos , Vitamina D/sangue , Estudos Prospectivos , Resultado do Tratamento , Estatísticas não Paramétricas , Escolaridade , Testes de Estado Mental e Demência , Memória/efeitos dos fármacos
9.
Synapse ; 71(11)2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28686793

RESUMO

In utero methamphetamine (MA) exposure leads to a range of adverse effects, such as decreased attention, reduced working-memory capability, behavioral dysregulation, and spatial memory impairments in exposed children. In the current experiment, preweaning Sprague-Dawley rats-as a model of third trimester human exposure-were administered the spin trapping agent, N-tert-butyl-α-phenylnitrone (PBN), daily prior to MA. Rats were given 0 (SAL) or 40 mg/kg PBN prior to each MA dose (10 mg/kg, 4× per day) from postnatal day (P) 6-15. Littermates underwent Cincinnati water maze, Morris water maze, and radial water maze assessment beginning on P30 (males) or P60 (females). Males were also tested for conditioned contextual and cued freezing, while females were trained in passive avoidance. Findings show that, regardless of age/sex, neonatal MA induced deficits in all tests, except passive avoidance. PBN did not ameliorate these effects, but had a few minor effects. Taken together, MA induced learning deficits emerge early and persist, but the mechanism remains unknown.


Assuntos
Deficiências da Aprendizagem/induzido quimicamente , Aprendizagem/efeitos dos fármacos , Memória/efeitos dos fármacos , Metanfetamina/toxicidade , Efeitos Tardios da Exposição Pré-Natal , Espécies Reativas de Oxigênio/metabolismo , Animais , Animais Recém-Nascidos , Antioxidantes/farmacologia , Óxidos N-Cíclicos/farmacologia , Modelos Animais de Doenças , Feminino , Reação de Congelamento Cataléptica/efeitos dos fármacos , Reação de Congelamento Cataléptica/fisiologia , Aprendizagem/fisiologia , Deficiências da Aprendizagem/metabolismo , Masculino , Memória/fisiologia , Fármacos Neuroprotetores/farmacologia , Gravidez , Distribuição Aleatória , Ratos Sprague-Dawley
10.
J Psychopharmacol ; 31(10): 1362-1368, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-28441901

RESUMO

STUDY HYPOTHESIS: In cases of deliberate self-poisoning (DSP), patients often ingest benzodiazepines (BZDs), known to alter memory. Experts recommend recovery of the patient's cognitive capacity before psychiatric assessment. Unfortunately, there is no validated tool in common practice to assess whether sufficient cognitive recovery has occurred after DSP with BZDs to ensure patient memory of the assessment. OBJECTIVE: The aim of the study was to identify cognitive functions and markers which predict preserved memory of the mental health care plan proposed at the emergency department after DSP. METHODS: We recruited patients admitted for DSP with BZDs and control patients. At the time of the psychiatric assessment, we performed cognitive tests and we studied the relationship between these tests and the scores of a memory test performed 24 h after. RESULTS: In comparison with the control group, we found memory impairment in the BZD group. We found significant impairment on the Trail Making Test A (TMT A) in the BZD group in comparison with the control group, while TMT A and Wechsler Adult Intelligence Scale (WAIS) Coding test scores were significantly correlated with memory scores. CONCLUSIONS: Attentional functions tested by WAIS Coding test and TMT A were correlated with memory score. It could be profitable to assess it in clinical practice prior to a psychiatric interview.


Assuntos
Benzodiazepinas/administração & dosagem , Benzodiazepinas/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Cognição/efeitos dos fármacos , Transtornos da Memória/induzido quimicamente , Memória/efeitos dos fármacos , Rememoração Mental/efeitos dos fármacos , Adulto , Idoso , Serviço Hospitalar de Emergência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Projetos Piloto , Psicoterapia/métodos , Adulto Jovem
11.
Support Care Cancer ; 25(2): 449-457, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27726029

RESUMO

PURPOSE: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. METHODS: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. RESULTS: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. CONCLUSIONS: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.


Assuntos
Biomarcadores Tumorais/líquido cefalorraquidiano , Transtornos Cognitivos/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/líquido cefalorraquidiano , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Atenção/efeitos dos fármacos , Criança , Pré-Escolar , Cognição/efeitos dos fármacos , Transtornos Cognitivos/líquido cefalorraquidiano , Transtornos Cognitivos/induzido quimicamente , Transtornos Cognitivos/etiologia , Função Executiva/efeitos dos fármacos , Feminino , Humanos , Injeções Espinhais , Masculino , Memória/efeitos dos fármacos , Leucemia-Linfoma Linfoblástico de Células Precursoras/psicologia , Sobreviventes , Adulto Jovem
12.
Eur J Nutr ; 56(6): 2093-2103, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27370643

RESUMO

PURPOSE: Although lower levels of vitamin D have been related to poor cognitive functioning and dementia in older adults, evidence from longitudinal investigations is inconsistent. The objective of this study was to determine whether 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels are associated with specified measures of cognitive decline in ageing men. METHODS: The European Male Ageing Study (EMAS) followed 3369 men aged 40-79 over 4.4 years. 25(OH)D levels at baseline were measured by radioimmunoassay, and 1,25(OH)2D levels were obtained with liquid chromatography-tandem mass spectrometry. Visuoconstructional abilities, visual memory, and processing speed at baseline and follow-up were assessed using the Rey-Osterrieth Complex Figure Test (ROCF), Camden Topographical Recognition Memory (CTRM), and the Digit Symbol Substitution Test (DSST). RESULTS: Following attritions, a total of 2430 men with a mean (SD) age of 59.0 (10.6) were included in the analyses. At baseline, the mean 25(OH)D concentration was 64.6 (31.5) nmol/l, and mean 1,25(OH)2D level was 59.6 (16.6) pmol/l. In age-adjusted linear regression models, high 25(OH)D concentrations were associated with a smaller decline in the DSST (ß = 0.007, p = 0.020). Men with low 25(OH)D levels (<50 nmol/l) showed a greater decline in the CTRM compared to men with higher (≥75 nmol/l) levels (ß = -0.41, p = 0.035). However, these associations disappeared after adjusting for confounders such as depressive symptoms, BMI, and comorbidities. There was no indication of a relationship between 1,25(OH)2D and decline in cognitive subdomains. CONCLUSION: We found no evidence for an independent association between 25(OH)D or 1,25(OH)2D levels and visuoconstructional abilities, visual memory, or processing speed over on average 4.4 years in this sample of middle-aged and elderly European men.


Assuntos
Envelhecimento/efeitos dos fármacos , Cognição/efeitos dos fármacos , Vitamina D/análogos & derivados , Adulto , Idoso , Disfunção Cognitiva/sangue , Disfunção Cognitiva/diagnóstico , Seguimentos , Comportamentos Relacionados com a Saúde , Humanos , Estilo de Vida , Masculino , Memória/efeitos dos fármacos , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Inquéritos e Questionários , Vitamina D/administração & dosagem , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/complicações , População Branca
13.
Compr Psychiatry ; 71: 95-105, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27653781

RESUMO

BACKGROUND: Hoasca (also called ayahuasca) is a N,N-dimethyltryptamine (DMT) - containing psychedelic brew originally used for magico-religious purposes by Amerindian populations of the Amazon Basin. Recently, Brazilian syncretic churches have helped spread the ritual use of hoasca to Western societies. The aim of this study was to evaluate substance use, and neuropsychological and psychological functioning of regular hoasca users within a religious setting. METHODS: Assessment of socio-economic status, mood, personality traits, impulsiveness, drug use, quality of life, extrinsic and intrinsic religiosity, and neuropsychological function was performed on 30 volunteers from a U.S. branch of União do Vegetal (UDV), a Brazilian religion which uses hoasca ritually. We also assessed 27 non-hoasca-using control subjects matched by socio-demographic profile and church attendance. Mann-Whitney U, chi-squared and Fisher tests were used to analyze differences between groups. Spearman's association and simple logistic regression tests were used to analyze the impact of frequency of hoasca use on dependent variables. RESULTS: Relative to the control group, the UDV group demonstrated lower scores for depression (p=0.043, r=.27) and confusion (p=0.032, r=.29) as assessed by the Profile of Mood States (POMS); higher scores on the instrument Big Five Inventory (BFI) for the personality traits agreeableness (p=0.028, r=.29) and openness (p=0.037, r=.28); higher scores on the quality life domain role limitations due to physical health as determined by the instrument Medical Outcomes Study Short Form-36 - SF-36 (p=0.035, r=.28); less recent use of alcohol (p<0.001, φc=.57), greater past use of alcohol to intoxication (p=0.007, φc=.36) and past use of cannabis (p=0.001, φc=.45) as measured by the Addiction Severity Index (ASI), 5th edition; better score on a measure of memory vulnerability to proactive interference as measured by the California Verbal Learning Test - CVLT (p=0.040, r=.27). Lifetime use of hoasca was positively correlated with role limitations due to physical health (p=0.032, rs=.39) and negatively associated with lifetime heavy alcohol use (p=0.034, OR=0.979). CONCLUSIONS: The findings indicate that religious use of hoasca does not adversely affect neuropsychological functioning and may have positive effects on substance abuse and mood.


Assuntos
Afeto/efeitos dos fármacos , Banisteriopsis , Usuários de Drogas/psicologia , Alucinógenos/farmacologia , Memória/efeitos dos fármacos , Personalidade/efeitos dos fármacos , Religião , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Inventário de Personalidade , Qualidade de Vida/psicologia , Adulto Jovem
14.
Bipolar Disord ; 18(2): 102-15, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27004564

RESUMO

OBJECTIVE: The aim of the present study was to characterize the neurocognitive effects of lithium in bipolar disorder to inform clinical and research approaches for further investigation. METHODS: Key words pertaining to neurocognition in bipolar disorder and lithium treatment were used to search recognized databases to identify relevant literature. The authors also retrieved gray literature (e.g., book chapters) known to them and examined pertinent articles from bibliographies. RESULTS: A limited number of studies have examined the effects of lithium on neurocognition in bipolar disorder and, although in some domains a consistent picture emerges, in many domains the findings are mixed. Lithium administration appears to reshape key components of neurocognition - in particular, psychomotor speed, verbal memory, and verbal fluency. Notably, it has a sophisticated neurocognitive profile, such that while lithium impairs neurocognition across some domains, it seemingly preserves others - possibly those vulnerable to the effects of bipolar disorder. Furthermore, its effects are likely to be direct and indirect (via mood, for example) and cumulative with duration of treatment. Disentangling the components of neurocognition modulated by lithium in the context of a fluctuating and complex illness such as bipolar disorder is a significant challenge but one that therefore demands a stratified and systematic approach, such as that provided by the Lithium Battery. CONCLUSIONS: In order to delineate the effects of lithium therapy on neurocognition in bipolar disorder within both research and clinical practice, a greater understanding and measurement of the relatively stable neurocognitive components is needed to examine those that indeed change with lithium treatment. In order to achieve this, we propose a Lithium Battery-Clinical and a Lithium Battery-Research that can be applied to these respective settings.


Assuntos
Transtorno Bipolar , Lítio/farmacologia , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/fisiopatologia , Transtorno Bipolar/psicologia , Cognição/efeitos dos fármacos , Humanos , Conduta do Tratamento Medicamentoso , Memória/efeitos dos fármacos , Testes Neuropsicológicos , Desempenho Psicomotor/efeitos dos fármacos
16.
Neurobiol Learn Mem ; 130: 149-58, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26899993

RESUMO

We here explore the utility of a paradigm that allows the simultaneous assessment of memory for object (what) and object location (where) and their comparative predominance. Two identical objects are presented during a familiarity trial; during the test trial one of these is displaced, and a new object is presented in a familiar location. When tested 5 or 80min later, rats explored both the novel and the displaced objects more than two familiar stationary objects, indicating intact memory for both, object and place. When tested 24h later rats explored the novel object more than the displaced familiar one, suggesting that forgetting differently influenced object and place memory, with memory for object being more robust than memory for place. Animals that received post-trial administration of the neurokinin-3 receptor agonist senktide and were tested 24h later, now explored the novel and displaced objects equally, suggesting that the treatment prevented the selective decay of memory for location. Next, animals received NMDA lesions in either the perirhinal cortex or the hippocampus, which are hypothesized to be preferentially involved in memory for objects and memory for place, respectively. When tested 5 or 80min later, the perirhinal cortex lesion group explored the displaced object more, indicating relatively deficient object memory, while the hippocampal lesion led to the opposite pattern, demonstrating comparatively deficient place memory. These results suggest different preferential engagement of the perirhinal cortex and hippocampus in their processing of memory for object and place. This preference test lends itself to application in the comparison of selective lesions of neural sites and projection systems as well as to the assessment of possible preferential action of pharmacological agents on neurochemical processes that subserve object vs place learning.


Assuntos
Hipocampo/fisiologia , Memória/fisiologia , Fragmentos de Peptídeos/farmacologia , Córtex Perirrinal/fisiologia , Receptores da Neurocinina-3/agonistas , Comportamento Espacial/fisiologia , Substância P/análogos & derivados , Animais , Hipocampo/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , N-Metilaspartato/toxicidade , Córtex Perirrinal/efeitos dos fármacos , Ratos , Ratos Wistar , Comportamento Espacial/efeitos dos fármacos , Substância P/farmacologia
17.
Hum Psychopharmacol ; 31(1): 19-28, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26563456

RESUMO

OBJECTIVE: Accumulating evidence is delineating a neuroprotective/neurotrophic role for lithium. However, its primary effects on cognition remain ambiguous. We sought to investigate the profile of cognitive impairment in patients with bipolar disorder and to determine whether continued treatment with lithium preserves cognitive functioning. METHODS: In this cross-sectional study, we tested 15 euthymic patients with bipolar I disorder undergoing long-term clinical maintenance treatment with lithium (for at least 12 months), 15 matched patients treated with other mood-stabilizing drugs and who had never received lithium, and 15 matched healthy subjects on the Cambridge Neuropsychological Test Automated Battery. Investigated cognitive domains were visual memory, executive functions, attention, decision-making/impulsivity, and response inhibition. We controlled for age, gender, intelligence, and residual psychiatric symptomatology. RESULTS: Taken together, bipolar patients demonstrated robust deficits in visual memory and executive functions. Once subdivided in treatment subgroups, only non-lithium bipolar patients demonstrated impairments in visual memory. Attention, decision-making, and response inhibition were preserved in both groups. No correlation emerged between neuropsychological tests performance, clinical, and psychological variables. CONCLUSIONS: This study is the first to our knowledge to have demonstrated, by means of a highly sensitive test of visual memory, a potential hippocampus neuroprotective effect of lithium in patients with bipolar disorder. Besides, it confirms prior findings of cognitive deficits in euthymic bipolar patients.


Assuntos
Antimaníacos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Compostos de Lítio/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Adulto , Antimaníacos/farmacologia , Estudos de Casos e Controles , Estudos Transversais , Feminino , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Humanos , Compostos de Lítio/farmacologia , Masculino , Memória/efeitos dos fármacos , Pessoa de Meia-Idade , Fármacos Neuroprotetores/farmacologia , Testes Neuropsicológicos
19.
Neurotoxicol Teratol ; 52(Pt A): 109-15, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26526903

RESUMO

Cognitive tests of learning and memory (L&M) have been required by U.S. Environmental Protection Agency (EPA) developmental neurotoxicity test (DNT) guidelines for more than two decades. To evaluate the utility of these guidelines, the EPA reviewed 69 pesticide DNT studies. This review found that the DNT provided or could provide the point-of-departure for risk assessment by showing the Lowest Observable Adverse Effect Level (LOAEL) in 28 of these studies in relation to other reported end points. Among the behavioral tests, locomotor activity and auditory/acoustic startle provided the most LOAELs, and tests of cognitive function and the Functional Observational Battery (FOB) the fewest. Two issues arose from the review: (1) what is the relative utility of cognitive tests versus tests of unconditioned behavior, and (2) how might cognitive tests be improved? The EPA sponsored a symposium to address this. Bushnell reviewed studies in which both screening (locomotor activity, FOB, reflex ontogeny, etc.) and complex tests (those requiring training) were used within the same study; he found relatively little evidence that complex tests provided a LOAEL lower than screening tests (with exceptions). Levin reviewed reasons for including cognitive tests in regulatory studies and methods and evidence for the radial arm maze and its place in developmental neurotoxicity assessments. Driscoll and Strupp reviewed the value of serial reaction time operant methods for assessing executive function in developmental neurotoxicity studies. Vorhees and Williams reviewed the value of allocentric (spatial) and egocentric cognitive tests and presented methods for using the Morris water maze for spatial and the Cincinnati water maze for egocentric cognitive assessment. They also reviewed the possible use of water radial mazes. The relatively lower impact of cognitive tests in previous DNT studies in the face of the frequency of human complaints of chemical-induced cognitive dysfunction indicates that animal cognitive tests need improvement. The contributors to this symposium suggest that if the guidelines are updated, they be made more specific by recommending preferred tests and providing greater detail on key characteristics of such tests. Additionally, it is recommended that guidance be developed to address important issues with cognitive tests and to provide the information needed to improve the design, conduct, and interpretation of tests of higher function within a regulatory context. These steps will maximize the value of cognitive tests for use in hazard evaluation and risk assessment.


Assuntos
Atenção/efeitos dos fármacos , Aprendizagem/efeitos dos fármacos , Memória/efeitos dos fármacos , Testes Neuropsicológicos , Neurotoxinas/toxicidade , Testes de Toxicidade/métodos , Animais , Humanos , Aprendizagem em Labirinto/efeitos dos fármacos , Medição de Risco , Estados Unidos , United States Environmental Protection Agency
20.
Phys Sportsmed ; 43(3): 227-35, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26200262

RESUMO

OBJECTIVES: Baseline and post-concussive neurocognitive testing is useful in managing concussed athletes. The Concussion in Sport Group has postulated that the use of psychotropic medications is a modifying factor in the management of sport-related concussion. About 7% of US adolescents are prescribed psychotropics in a given year. Our aim was to investigate whether psychotropic medication use or psychiatric illness is associated with differences in baseline neurocognitive test scores. METHODS: From 2007 to 2012, over 7000 athletes underwent pre-participation baseline neurocognitive testing using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery. Following application of inclusion and exclusion criteria, athletes' self-reported medication lists were reviewed and: 1) classified as psychotropic or not and 2) subclassified. Group subclassification yielded: 1) use of any psychotropic medication, 2) psychostimulant use, 3) antidepressant use and 4) self-reported history of depression and/or anxiety without psychotropic use. Each group was matched, by sex, age, body mass index, education level and concussion history with athletes who were not reportedly prescribed psychotropic medications or did not report a depression/anxiety history, respectively. Each group's baseline ImPACT scores were compared to matched controls. RESULTS: The use of prescribed psychotropic medications without regard to subclass had no effect on baseline ImPACT composite scores among athletes ages 13-25. However, athletes reportedly prescribed psychostimulants displayed significantly lower visual motor speed scores (32.8 vs 37.1, p = 0.030) and slower reaction times (0.65 vs 0.60, p = 0.044) than non-users. In contrast, antidepressant users displayed significantly faster reaction times (0.58 vs 0.61, p = 0.029). Those reporting a history of depression/anxiety, not treated with psychotropics, displayed significantly lower visual memory (70.4 vs 75.2, p = 0.010) and higher symptom scores (8.83 vs 4.72, p = 0.005). CONCLUSIONS: This pilot study suggests that self-reported psychotropic medications are associated with differences in baseline ImPACT test scores, which appear dependent on medication subclass. Our preliminary results support the inclusion of psychotropic medications, specifically psychostimulants and antidepressants, as well as history of depression/anxiety as potential concussion modifiers.


Assuntos
Testes Neuropsicológicos , Psicotrópicos/uso terapêutico , Adolescente , Adulto , Antidepressivos/uso terapêutico , Ansiedade/psicologia , Traumatismos em Atletas/diagnóstico , Concussão Encefálica/diagnóstico , Depressão/tratamento farmacológico , Depressão/psicologia , Feminino , Humanos , Masculino , Memória/efeitos dos fármacos , Projetos Piloto , Tempo de Reação , Autorrelato , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA